Vaxart, Inc. to Participate in September Virtual Investor Conferences

A link to the webcasts along with a replay of the webcasts will be accessible on the Events & Presentations page of the Investors section on the Companys website.

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Thursday, September 3, 2020

Information

Tags:

Cancer, Medical specialties, Clinical medicine, RTT, Papillomavirus, Vaxart, Infectious causes of cancer, Virology, Vaccine, Human papillomavirus infection, Papillomaviridae, HPV vaccine

Geotags:

Organisation:

VAXART, INC.

Summary

Key Points:

A link to the webcasts along with a replay of the webcasts will be accessible on the Events & Presentations page of the Investors section on the Companys website.
Vaxart is a clinical-stage biotechnology company focused on developing oral tablet vaccines designed to generate mucosal and systemic immune responses that protect against a wide range of infectious diseases and has the potential to provide sterilizing immunity for diseases such as COVID-19.
Vaxarts development programs include oral tablet vaccines that are designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV).
For more information, please visit www.vaxart.com.

- H.C. Wainwright: 22^nd Annual Global Investment Conference - September 14^th– 16^th- Sachs Associates: 20^th Annual Biotech in Europe Forum - September 21^st – 24^th- SVB Leerink: CybeRx Series: Vaccine Forum - September 23^rd & – 24^th

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced senior management will participate in the following conferences in the month of September and invites investors to participate by webcast. Please see additional details below:

H.C. Wainwright: 22^nd Annual Global Investment Conference
Title:	Vaxart, Inc. (VXRT) Company Presentation / Fireside Chat
Date:	Monday, September 14^th 2020
Time:	10:30 am Eastern Time
Presenter:	Andrei Floroiu, President & CEO

Sachs Associates: 20^th Annual Biotech in Europe Forum
Title (1):	Pandemic Response Day: *Vaccine Panel*
Date:	Monday, September 21^st 2020
Time:	13:05 -14:00 Central European Time
Panelists:	Andrei Floroiu, President & CEO Vaxart, Inc.
	Andrew Allen, Co-Founder, President & CEO, Gritstone Oncology
	Frederic Ors, CEO, IMV, Inc.
	Johan Van Hoof, Global Therapeutic Area Head, IDV Vaccines, Johnson & Johnson

Title (2):	Spotlight Showcase Vaxart, Inc. (VXRT) Company Presentation
Date:	Monday, September 21^st 2020
Time:	14:05 -14:25 Central European Time
Presenter:	Andrei Floroiu, President & CEO Vaxart, Inc.

SVB LEERINK: CybeRx Series – Vaccine Forum
Title:	Vaxart, Inc. (VXRT) - Fireside Chat
Date:	Wednesday, September 23^rd 2020
Time:	2:00 am Eastern Time
Presenters:	Andrei Floroiu, President & CEO
	Sean Tucker, Ph.D., Founder & Chief Scientific Officer

Webcast Links

A link to the webcasts along with a replay of the webcasts will be accessible on the Events & Presentations page of the Investors section on the Company’s website.

About Vaxart

Vaxart is a clinical-stage biotechnology company focused on developing oral tablet vaccines designed to generate mucosal and systemic immune responses that protect against a wide range of infectious diseases and has the potential to provide sterilizing immunity for diseases such as COVID-19. Vaxart believes that a room temperature stable tablet vaccine is easier to distribute, store and administer than injectable vaccines and may provide significantly faster response to a pandemic than injectable vaccines, enabling a greater portion of the population to be protected. Vaxart’s development programs include oral tablet vaccines that are designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). For more information, please visit www.vaxart.com.

Contacts

Investors:
Joyce Allaire
LifeSci Advisors
[email protected]
617.435.6602

Media:
Gloria Gasaatura
LifeSci Communications
[email protected]
646.970.4688